SIMVASTATIN (MK 733) IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - A 2-YEAR TRIAL

被引：0
|
作者：
LECLERCQ, V
HARVENGT, C
机构：
[1] CATHOLIC UNIV LOUVAIN, PHARMACOTHERAPY LAB, 53 AVE E MOUNIER, B-1200 BRUSSELS, BELGIUM
[2] ST LUC UNIV CLIN, DEPT INTERNAL MED, B-1200 BRUSSELS, BELGIUM
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 1989年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：76 / 81
页数：6
相关论文
共 50 条
  • [21] LOW-DOSE EFFECT OF SIMVASTATIN (MK-733) ON SERUM-LIPIDS, LIPOPROTEINS, AND APOLIPOPROTEINS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
    SAKU, K
    SASAKI, J
    ARAKAWA, K
    CLINICAL THERAPEUTICS, 1989, 11 (02) : 247 - 257
  • [22] COMPARATIVE EFFECTS OF SIMVASTATIN (MK-733) AND PRAVASTATIN (CS-514) ON HYPERCHOLESTEROLEMIA INDUCED BY CHOLESTEROL FEEDING IN RABBITS
    ISHIDA, F
    WATANABE, K
    SATO, A
    TAGUCHI, K
    KAKUBARI, K
    KITANI, K
    KAMEI, T
    BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1042 (03) : 365 - 373
  • [23] Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations
    Sijbrands, EJG
    Lombardi, MP
    Westendorp, RGJ
    Leuven, JAG
    Meinders, AE
    Van der Laarse, A
    Frants, RR
    Havekes, LM
    Smelt, AHM
    ATHEROSCLEROSIS, 1998, 136 (02) : 247 - 254
  • [24] The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia
    Pappu, AS
    Illingworth, DR
    ATHEROSCLEROSIS, 2002, 165 (01) : 137 - 144
  • [25] INFLUENCE OF APO-E POLYMORPHISM ON THE RESPONSE TO SIMVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    DEKNIJFF, P
    STALENHOEF, AFH
    MOL, MJTM
    LEUVEN, JAG
    SMIT, J
    ERKELENS, DW
    SCHOUTEN, J
    FRANTS, RR
    HAVEKES, LM
    ATHEROSCLEROSIS, 1990, 83 (01) : 89 - 97
  • [26] SHORT-TERM EFFECTS OF TREATMENT WITH SIMVASTATIN ON TESTICULAR FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    PURVIS, K
    TOLLEFSRUD, A
    RUI, H
    HAUG, E
    NORSETH, J
    VIKSMOEN, L
    OSE, L
    LUND, H
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (01) : 61 - 64
  • [27] A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
    Langslet, Gisle
    Breazna, Andrei
    Drogari, Euridiki
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1153 - 1162
  • [28] Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia
    Sánchez-Quesada, JL
    Otal-Entraigas, C
    Franco, M
    Jorba, O
    González-Sastre, F
    Blanco-Vaca, F
    Ordóñez-Llanos, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (06): : 655 - 659
  • [29] PREVENTIVE EFFECT OF MK-733 (SIMVASTATIN), AN INHIBITOR OF HMG-COA REDUCTASE, ON HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS INDUCED BY CHOLESTEROL FEEDING IN RABBITS
    KOBAYASHI, M
    ISHIDA, F
    TAKAHASHI, T
    TAGUCHI, K
    WATANABE, K
    OHMURA, I
    KAMEI, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 1989, 49 (01): : 125 - 133
  • [30] Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial
    Kastelein, JP
    Sager, PT
    de Groot, E
    Veltri, E
    AMERICAN HEART JOURNAL, 2005, 149 (02) : 234 - 239
12345